Bryone Kuss

8PUBLICATIONS
61CO-AUTHORS
Language documentation and descriptionThermodynamics and statistical physicsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 07, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

|Aug 28, 2025
HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.

Elizabeth Hughes, Sue Latham, Bryone Kuss

|Aug 22, 2025
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.

Nirav N Shah, Pier Luigi Zinzani, Michael Wang

|Jun 07, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.

John N Allan, Ian W Flinn, Tanya Siddiqi

|Jun 15, 2022
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.

Stephen P Mulligan, Stephen Opat, Paula Marlton

|Oct 07, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.

William G Wierda, John N Allan, Tanya Siddiqi

Pageof 2

Frequent Collaborators

4 joint publications

Constantine Si Lun Tam

3 joint publications

Oliver G Best

3 joint publications

Stephen Opat

2 joint publications

Lauren Thurgood